{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:37:29Z","timestamp":1791891449222,"version":"4.3.4"},"reference-count":125,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005115","type":"journal-article","created":{"date-parts":[[2005,1,17]],"date-time":"2005-01-17T06:20:27Z","timestamp":1105942827000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Rofecoxib for osteoarthritis"],"prefix":"10.1002","volume":"2010","author":[{"given":"Sarah E","family":"Garner","sequence":"first","affiliation":[{"name":"National Institute for Clinical Excellence; Appraisals Team; MidCity Place 71 High Holborn London UK WC1V 6NA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dogan","family":"Fidan","sequence":"additional","affiliation":[{"name":"Aventis Pharma Ltd.; Health Economics Unit; Flat 8 291 Boardwalk Place London UK E14 56E"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth R","family":"Frankish","sequence":"additional","affiliation":[{"name":"National Institute for Clinical Excellence; Appraisals Team; MidCity Place 71 High Holborn London UK WC1V 6NA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Maxwell","sequence":"additional","affiliation":[{"name":"University of Ottawa; Institute of Population Health; 1 Stewart Street Ottawa Ontario Canada K1N 6N5"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,1,24]]},"reference":[{"key":"10.1002\/14651858.CD005115-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/030097401750065274","article-title":"Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis","volume":"30","author":"Acevedo","year":"2001","journal-title":"Scand J Rheumatol"},{"key":"10.1002\/14651858.CD005115-BIB0002|cit2","unstructured":"Laurenzi M Vandormael K Daniels B Seidenberg B Nuyen K Vala M Comparison of the tolerability profile of rofecoxib and Arthrotec(TM) in patients with osteoarthritis-study design and baseline characteristics [poster] EULAR 2000"},{"key":"10.1002\/14651858.CD005115-BIB0003|cit3","unstructured":"Laurenzi M Vandormael K Malice MP Jasan J Vala M Justice S Bozalis D Comparison of the tolerability profile of rofecoxib and Arthrotec(TM) in patients with osteoarthritis [poster] EULAR 2000"},{"key":"10.1002\/14651858.CD005115-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"Geba GP Lisse JR Perlman M Polis AB Dixon ME Skalky CS Gastrointestinal tolerability in primary care patients treated with naproxen or rofecoxib for osteoarthritis: the ADVANTAGE trial EULAR abstract SAT0096, Prague 2001","DOI":"10.1136\/annrheumdis-2001.471"},{"key":"10.1002\/14651858.CD005115-BIB0005|cit5","unstructured":"Geba GP Lisse JR Perlman M Polis AB Dixon ME Skalky CS The efficacy of rofecoxib versus naproxen in osteoarthritis: subgroup analysis by joint in the advantage trial EULAR abstract THU0248 2000"},{"key":"10.1002\/14651858.CD005115-BIB0006|cit6","unstructured":"Geba GP Polis AB Bohidar NR Edema adverse experiences in 5557 osteoarthritis patients treated with rofecoxib compared to naproxen in the ADVANTAGE trial: a multivariate analysis [abstract] ACR Annual Scientific Meeting, New Orleans 2002"},{"key":"10.1002\/14651858.CD005115-BIB0007|cit7","unstructured":"Geba GP Polis AB Bohidar NR Hypertension among rofecoxib compared to naproxen in the ADVANTAGE trial: a multivariate analysis ACR Annual Scientific meeting, New Orleans 2002"},{"key":"10.1002\/14651858.CD005115-BIB0008|cit8","unstructured":"Geba GP Polis AB Bohidar NR Hypertension and oedema related adverse events among diabetic patients treated with rofecoxib or naproxen in the population of and osteoarthritis trial: ADVANTAGE ACR, Orlando 2003"},{"key":"10.1002\/14651858.CD005115-BIB0009|cit9","unstructured":"Geba GP Polis AB Bohidar NR Petruschke RA Dobbins TW Rush JR Keane WF Effect of rofecoxib versus naproxen: hypertension and edema adverse events in a multivariate analysis involving 5557 patients from the ADVANTAGE trial EULAR abstract THU0220 2000"},{"key":"10.1002\/14651858.CD005115-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Geba GP Polis AB Dixon MB Skalky CS Myers DA Higginbotham JA Caldwell JR Wingert KJ Gormley GJ Gastrointestinal tolerability in primary care patients treated with naproxen or rofecoxib for osteoarthritis(OA): the ADVANTAGE trial EULAR conference 2000","DOI":"10.1136\/annrheumdis-2001.471"},{"key":"10.1002\/14651858.CD005115-BIB0011|cit11","unstructured":"Geba GP Polis AB Shalky CS Petruschke RA Dobbins TW Rofecoxib versus naproxen in osteoarthritis patients receiving concomitant low dose aspirin: a sub-group analysis involving 719 patients from the ADVANTAGE trial EULAR abstract THU0252 2000"},{"key":"10.1002\/14651858.CD005115-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Geba GP Polis AB Skalky CS Gastrointestinal tolerability among osteoarthritis patients receiving low dose aspirin in combination with rofecoxib or naproxen [absract] ACR New Orleans 2002","DOI":"10.1016\/S0002-9270(02)05200-0"},{"key":"10.1002\/14651858.CD005115-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.7326\/0003-4819-139-7-200310070-00005","article-title":"Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis. A randomised controlled trial","volume":"139","author":"Lisse","year":"2003","journal-title":"Annals of Internal Medicine"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD005115-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00003495-200363001-00006","article-title":"A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee","volume":"63","author":"Bianchi","year":"2003","journal-title":"Drugs"},{"issue":"5","key":"10.1002\/14651858.CD005115-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0","article-title":"Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group","volume":"43","author":"Cannon","year":"2000","journal-title":"Arthritis & Rheumatism"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD005115-BIB0016|cit16","first-page":"Abstract 983","article-title":"MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26-week controlled clinical trial [abstract]","volume":"41","author":"Cannon","year":"1998","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD005115-BIB0017|cit17","unstructured":"Cannon GW Krupa D Sperling R Truitt K Two-year efficacy of rofecoxib and diclofenac in treatment of knee and hip osteoarthritis [abstract] Eular, Lisbon 2003"},{"key":"10.1002\/14651858.CD005115-BIB0018|cit18","unstructured":"Cannon GW Krupa DA McCormick CL Mehta A Reicin AS Rofecoxib has a lower incidence of increased liver function tests and LFT-related adverse events in comparison to diclofenac [abstact] EULAR, Lisbon 2003"},{"issue":"5,2","key":"10.1002\/14651858.CD005115-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"11A","DOI":"10.1016\/S0895-7061(03)00109-2","article-title":"Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure: results of a randomized double blind controlled trial in treated hypertensive patients with osteoarthritis (oa) and type 2 diabetes mellitus?","volume":"16 supplement","author":"Sowers","year":"2003","journal-title":"American Journal of Hypertension"},{"key":"10.1002\/14651858.CD005115-BIB0020|cit20","doi-asserted-by":"crossref","unstructured":"Sowers J van Ingen H White W Rofecoxib but not celecoxib, at doses providing equal OA efficacy increases mean 24-hour systolic blood pressure in treated hypertensive patients with osteoarthritis and type 2 diabetes mellitus [abstract] EULAR, Lisbon Abstract FRI0279 2003","DOI":"10.1016\/S0895-7061(03)00109-2"},{"key":"10.1002\/14651858.CD005115-BIB0021|cit21","unstructured":"Day RO Luza A Castaneda O MK-0966, a specific cox-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip OA in a 6 week controlled trial; XIV European League against Rheumatism Congress, [abstract] EULAR"},{"issue":"12","key":"10.1002\/14651858.CD005115-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/archinte.160.12.1781","article-title":"A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib\/Ibuprofen Comparator Study Group","volume":"160","author":"Day","year":"2000","journal-title":"Archives of Internal Medicine"},{"issue":"11","key":"10.1002\/14651858.CD005115-BIB0023|cit23","first-page":"2438","article-title":"Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group","volume":"26","author":"Ehrich","year":"1999","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD005115-BIB0024|cit24","first-page":"609","article-title":"Effect of rofecoxib on measures of health-related quality of life in patients with osteoarthritis","volume":"7","author":"Ehrich","year":"2001","journal-title":"American Journal of Managed Care"},{"issue":"suppl 2","key":"10.1002\/14651858.CD005115-BIB0025|cit25","first-page":"119 abstract 19","article-title":"The effect of MK-0966 (Vioxx), a cox-2 specific inhibitor, on health related quality of life in osteoarthritis patients","volume":"27","author":"Ehrich","year":"1998","journal-title":"Rheumatology Europe"},{"issue":"suppl 9","key":"10.1002\/14651858.CD005115-BIB0026|cit26","first-page":"Abstract 330","article-title":"MK-966, a highly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis (OA) of the knee and hip in a 6-week placebo controlled study [abstract]","volume":"40","author":"Ehrich","year":"1997","journal-title":"Arthritis & Rheumatism"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005115-BIB0027|cit27","first-page":"119 abstract 19","article-title":"Treatment with MK-966 (Vioxx), a specific cox-2 inhibitor, resulted in clinical improvement in osteoarthritis (OA) of the knee and hip, that was sustained over six months","volume":"27","author":"Ehrich","year":"1998","journal-title":"Rheumatology Europe"},{"key":"10.1002\/14651858.CD005115-BIB0028|cit28","unstructured":"Geba GP Polis AB Najarian DK Onset of efficacy and patient assessment of clinical response in osteoarthritis (OA): comparison of rofecoxib to nabumetone American Geriatric Society 2001"},{"key":"10.1002\/14651858.CD005115-BIB0029|cit29","unstructured":"Weaver AL Polis AB Petruschke RA Onset of efficacy of rofecoxib compared to nabumetone and placebo in patients with osteoarthritis EULAR 2003"},{"key":"10.1002\/14651858.CD005115-BIB0030|cit30","unstructured":"Weaver AL Polis AB Petruschke RA Najarian DK Geba GP Onset of efficacy of rofecoxib compared to nabumetone and placebo in patients with osteoarthritis -"},{"issue":"11","key":"10.1002\/14651858.CD005115-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1002\/art.11330","article-title":"Comparing the effiacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis","volume":"48","author":"Gibofsky","year":"2003","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD005115-BIB0032|cit32","unstructured":"Pincus T Gibofsky A Williams G McKenna F Celecoxib 200mg QD and rofecoxib 25mg QD show similar efficacy in the treatment of a flare of osteoarthritis of the knee EULAR abstracts online 2002"},{"issue":"2","key":"10.1002\/14651858.CD005115-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D","article-title":"Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group","volume":"43","author":"Hawkey","year":"2000","journal-title":"Arthritis & Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD005115-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/00045391-200311000-00017","article-title":"Comparative Evaluation of the Effectiveness and Tolerability of Nimesulide Versus Rofecoxib Taken Once a Day in the Treatment of Patients with Knee Osteoarthritis","volume":"10","author":"Herrera","year":"2003","journal-title":"American Journal of Therapeutics"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD005115-BIB0035|cit35","first-page":"Abstract 440","article-title":"Rofecoxib results in superior clinical response compared to nabumetone in the treatment of osteoarthritis","volume":"42","author":"Geba","year":"1999","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD005115-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1532-5415.2004.52201.x","article-title":"Efficacy and safety of rofecoxib 12.5mg versus nabumetone 1000mg in patients with osteoarthritis of the knee: a randomised controlled trial","volume":"52","author":"Kivitz","year":"2004","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD005115-BIB0037|cit37","unstructured":"Laurenzi M Geba G Polis A Dixon M Brady P Green JA Evaluation of onset of action of rofecoxib, naproxen and nabumetone in patients with osteoarthritis (OA) [poster] EULAR 2000 2000"},{"key":"10.1002\/14651858.CD005115-BIB0038|cit38","unstructured":"Weaver AL Polis AB Petruschke RA Onset of efficacy of rofecoxib compared to nabumetone and placebo in patients with osteoarthritis EULAR 2003"},{"issue":"4","key":"10.1002\/14651858.CD005115-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0016-5085(99)70334-3","article-title":"A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis.Rofecoxib Osteoarthritis Endoscopy Study Group [see comments]","volume":"117","author":"Laine","year":"1999","journal-title":"Gastroenterology"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD005115-BIB0040|cit40","first-page":"S145-Abstract 4","article-title":"Randomized study of rofecoxib, a cyclooxygenase-2 specific inhibitor, on the gastroduodenal mucosa of osteoarthritis","volume":"42","author":"Laine","year":"1999","journal-title":"Arthritis & Rheumatism"},{"issue":"Supplement 3","key":"10.1002\/14651858.CD005115-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00124743-200106000-00004","article-title":"Cox-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled randomised, double-blind study","volume":"7","author":"McKenna","year":"2001","journal-title":"Journal of Clinical Rheumatology"},{"key":"10.1002\/14651858.CD005115-BIB0042|cit42","doi-asserted-by":"crossref","unstructured":"McKenna F Weaver AL Fiechtner JI Bello AE Fort J CoX-2 specific inhibitors in the management of osteoarthritis of the knee- a placebo-controlled randomised,double-blind study [poster] EULAR conference 2000","DOI":"10.1097\/00124743-200106000-00004"},{"key":"10.1002\/14651858.CD005115-BIB0043|cit43","unstructured":"Moskowitz RW Jones RB Cawkwell G Valdecoxib 10mg demonstrates a rapid onset of action following a single dose in patients with OA of the knee in a flare state [abstract EULAR FRI 0277 2003"},{"key":"10.1002\/14651858.CD005115-BIB0044|cit44","unstructured":"Laurenzi M Geba G Polis A Dixon M Brady P Green JA Evaluation of onset of action of rofecoxib, naproxen and nabumetone in patients with osteoarthritis (OA) [poster] EULAR 2000"},{"key":"10.1002\/14651858.CD005115-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/030097402320817059","article-title":"Comparison of low-dose rofecoxib versus 1000mg naproxen in patients with osteoarthritis","volume":"31","author":"Myllykangas-Luosujarvi","year":"2002","journal-title":"Scandanavian Journal of Rheumatology"},{"key":"10.1002\/14651858.CD005115-BIB0046|cit46","first-page":"201","article-title":"Renal tolerability of three commonly employed non-steroidal anti-inflammatory drugs in elderly patients with osteoarthritis","volume":"20","author":"Niccoli","year":"2002","journal-title":"Clinical and Exeprimental Rheumatology"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD005115-BIB0047|cit47","first-page":"Abstract 242","article-title":"MK-0966, a specific COX-2 inhibitor has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6-week controlled clinical trial [abstract]","volume":"41","author":"Saag","year":"1998","journal-title":"Arthritis & Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD005115-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/archfami.9.10.1124","article-title":"Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy comparable with other nonsteroidal anti-inflammatory drugs","volume":"9","author":"Saag","year":"2000","journal-title":"Archives of Family Medicine"},{"key":"10.1002\/14651858.CD005115-BIB0049|cit49","unstructured":"Acevedo E Romanowicz A Heijde DVd Rofecoxib, a cox-2 specific inhibitor (C-2 SI), had clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a one-year controlled clinical trial; XIV European League against Rheumatism Congress, [abstract] EULAR"},{"key":"10.1002\/14651858.CD005115-BIB0050|cit50","unstructured":"Cannon GW Krupa D Sperling R Truitt K Two-year efficacy of rofecoxib and diclofenac in treatment of knee and hip osteoarthritis [abstract] Eular, Lisbon 2003"},{"key":"10.1002\/14651858.CD005115-BIB0051|cit51","unstructured":"Cannon GW Krupa DA McCormick CL Mehta A Reicin AS Rofecoxib has a lower incidence of increased liver function tests and LFT-related adverse events in comparison to diclofenac [abstact] EULAR, Lisbon 2003"},{"issue":"10","key":"10.1002\/14651858.CD005115-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/archfami.9.10.1124","article-title":"Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy comparable with other nonsteroidal anti-inflammatory drugs","volume":"9","author":"Saag","year":"2000","journal-title":"Archives of Family Medicine"},{"key":"10.1002\/14651858.CD005115-BIB0053|cit53","doi-asserted-by":"crossref","unstructured":"Geba GP Polis AB Dixon ME Dobbins TW Rush JE Weir MR Comparative blood pressure effects of rofecoxib, celecoxib, and placebo in patients with osteoarthritis: a randomised controlled trial EULAR 2002","DOI":"10.1136\/annrheumdis-2001.470"},{"key":"10.1002\/14651858.CD005115-BIB0054|cit54","doi-asserted-by":"crossref","unstructured":"Schnitzer TJ Kivitz AJ Greenwald M Fleischmann RM Matzura- Wolfe D Polis AB Dixon ME Dobbins PW Geba GP Rofecoxib provides superior relief of symptoms of osteoarthritis(OA) compared to celecoxib EULAR conference abstracts 2001","DOI":"10.1136\/annrheumdis-2001.464"},{"issue":"15 Supplement","key":"10.1002\/14651858.CD005115-BIB0056|cit55","first-page":"S371","article-title":"Cyclooxygenase-2 specific inhibitors and cardiorenal function: a randomised controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients","volume":"8","author":"Whelton","year":"2002","journal-title":"American Journal of Managed Care"},{"key":"10.1002\/14651858.CD005115-BIB0055|cit56","doi-asserted-by":"crossref","unstructured":"Whelton A Fort J Puma J Normandin D Bello AE Verburg KM Cyclooxygenase-2 specific inhibitors and cardiorenal function: a randomised controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients [poster] EULAR 2000","DOI":"10.1097\/00045391-200103000-00003"},{"key":"10.1002\/14651858.CD005115-BIB0058|cit57","doi-asserted-by":"crossref","unstructured":"Whelton A White W Bello A Puma J Blood pressure control and edema rates in older patients with hypertension and osteoarthritis following treatment with COX-2 specific inhibitors EULAR confernce proceedings 2002","DOI":"10.1016\/S0735-1097(02)81094-4"},{"issue":"9","key":"10.1002\/14651858.CD005115-BIB0057|cit58","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0002-9149(02)02661-9","article-title":"Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertenision and osteoarthritis","volume":"90","author":"Whelton","year":"2002","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD005115-BIB0059|cit59","doi-asserted-by":"crossref","unstructured":"White W Whelton A Bello A Puma J Rofecoxib but not celecoxib increases systolic blood pressure in hypertensive patients treated with ACE inhibitors and beta blockers EULAR 2002","DOI":"10.1016\/S0735-1097(02)81114-7"},{"key":"10.1002\/14651858.CD005115-BIB0060|cit60","unstructured":"Truitt K Ettinger W Schnitzer TJ Rofecoxib, a Cox-2 specific inhibitor had a clinical efficacy and overall safety in treating OA patients over 80 years and older; XIV European League against Rheumatism Congress, [abstract]. 6-11 June, Glasgow 1999 EULAR 1999"},{"key":"10.1002\/14651858.CD005115-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/BF03351533","article-title":"A multicenter, randomised, controlled trial to evaluate the safety profile, tolerability and efficacy of rofecoxib in advanced elderly patients with osteoarthritis","volume":"13","author":"Truitt","year":"2001","journal-title":"Aging Clin Exp Res"},{"key":"10.1002\/14651858.CD005115-BIB0062|cit62","doi-asserted-by":"crossref","unstructured":"Geba G Polis A Petruschke R Keane W Hypertension adverse experiences among osteoarthritis patients treated with rofecoxib, celecoxib or acetaminophen in the 'VACT' trials [abstract] EULAR, Lisbon 2003","DOI":"10.1016\/S0735-1097(03)82451-8"},{"key":"10.1002\/14651858.CD005115-BIB0063|cit63","unstructured":"Geba G Weaver A Polis A Pooled analysis of the VACT studies: the response of osteoarthritis patients to therapy with rofecoxib, celecoxib or acetaminophen [Abstract] American Pain Society, Poster 826 2003"},{"key":"10.1002\/14651858.CD005115-BIB0064|cit64","doi-asserted-by":"crossref","unstructured":"Geba G Weaver A Polis A Petruschke R Schnitzer T The response of osteoarthritis patients to therapy with rofecoxib, celecoxib or acetaminophen: a pooled analysis of the VACT trials [abstract] EULAR, Lisbon 2003","DOI":"10.1016\/S0735-1097(03)82451-8"},{"key":"10.1002\/14651858.CD005115-BIB0065|cit65","unstructured":"Geba G Weaver AL Schnitzer TJ Polis A Dixon M Kivitz AJ A clinical trial comparing rofecoxib to celecoxib and paracetamol in the treatment of osteoarthritis (OA): early efficacy results Eular conference proceedings 2000"},{"key":"10.1002\/14651858.CD005115-BIB0066|cit66","doi-asserted-by":"crossref","unstructured":"Geba GP Schnitzer TJ Polis AB Patient global assessment and WOMAC response among osteoarthritis patients treated with rofecoxib, celecoxib or acetaminophen in the VACT-2 trial EULAR 2003","DOI":"10.1016\/S0895-7061(03)00166-3"},{"key":"10.1002\/14651858.CD005115-BIB0067|cit67","first-page":"989A","article-title":"Correction","volume":"287","author":"Geba","year":"2002","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD005115-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.287.1.64","article-title":"Efficacy of rofecoxib, celecoxib and acetaminophen in osteoarthritis of the knee","volume":"287","author":"Geba","year":"2002","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD005115-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Geba G Polis A Petruschke R Keane W Hypertension adverse experiences among osteoarthritis patients treated with rofecoxib, celecoxib or acetaminophen in the 'VACT' trials [abstract] EULAR, Lisbon 2003","DOI":"10.1016\/S0735-1097(03)82451-8"},{"key":"10.1002\/14651858.CD005115-BIB0070|cit70","unstructured":"Geba G Weaver A Polis A Pooled analysis of the VACT studies: the response of osteoarthritis patients to therapy with rofecoxib, celecoxib or acetaminophen [Abstract] American Pain Society, Poster 826 2003"},{"key":"10.1002\/14651858.CD005115-BIB0071|cit71","doi-asserted-by":"crossref","unstructured":"Geba G Weaver A Polis A Petruschke P Schnitzer T Analysis of the onset of efficacy with rofecoxib, celecoxib and acetaminophen in osteoarthritis: the VACT-2 trial EULAR, Lisbon 2003","DOI":"10.1001\/jama.287.1.64"},{"key":"10.1002\/14651858.CD005115-BIB0072|cit72","doi-asserted-by":"crossref","unstructured":"Geba G Weaver A Polis A Petruschke R Schnitzer T The response of osteoarthritis patients to therapy with rofecoxib, celecoxib or acetaminophen: a pooled analysis of the VACT trials [abstract] EULAR, Lisbon 2003","DOI":"10.1016\/S0735-1097(03)82451-8"},{"key":"10.1002\/14651858.CD005115-BIB0073|cit73","doi-asserted-by":"crossref","unstructured":"Geba GP Schnitzer TJ Polis AB Patient global assessment and WOMAC response among osteoarthritis patients treated with rofecoxib, celecoxib or acetaminophen in the VACT-2 trial EULAR 2003","DOI":"10.1016\/S0895-7061(03)00166-3"},{"key":"10.1002\/14651858.CD005115-BIB0074|cit74","doi-asserted-by":"crossref","unstructured":"Geba GP Weaver AL Polis AB Onset of efficacy with rofecoxib, celecoxib and acetaminophen in osteoarthritis: the VACT-2 trial American Pain Society 2003","DOI":"10.1001\/jama.287.1.64"},{"key":"10.1002\/14651858.CD005115-BIB0075|cit75","unstructured":"Geba GP Weaver AL Polis AB Response of osteoarthritis patients to therapy with rofecoxib, celecoxib or paracetamol Presented at Pain in Europe IV, 4th Congress of the European Federation of IASP Chapters, Prague, Czech Republi"},{"issue":"9","key":"10.1002\/14651858.CD005115-BIB0076|cit76","first-page":"1670-Abstract 2","article-title":"COX-2 specific inhibition with MK-096625 or 50 mg Q.D. does not increase intestinal permeability [abstract]","volume":"93","author":"Bjarnason","year":"1998","journal-title":"American journal of Gastroenterology"},{"key":"10.1002\/14651858.CD005115-BIB0077|cit77","doi-asserted-by":"crossref","unstructured":"Eskiyurt N The first experience of the efficacy and safety of coxibs in turkish nation EULAR conference abstracts 2001","DOI":"10.1136\/annrheumdis-2001.403"},{"key":"10.1002\/14651858.CD005115-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1185\/030079902125000354","article-title":"A comparison of adverse renovascular experiences among osteoarthritis patients treateed with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents","volume":"18","author":"Gertz","year":"2002","journal-title":"Current Medical Research and Opinion"},{"issue":"6","key":"10.1002\/14651858.CD005115-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1046\/j.1365-2036.1999.00529.x","article-title":"Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen","volume":"13","author":"Lanza","year":"1999","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD005115-BIB0080|cit80","first-page":"9","article-title":"Outcome of specific COX-2 inhibition in rheumatoid arthritis","volume":"24 Suppl 49","author":"Lipsky PE","year":"1997","journal-title":"J-Rheumatol"},{"issue":"10","key":"10.1002\/14651858.CD005115-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0149-2918(99)80045-9","article-title":"Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial","volume":"21","author":"Malmstrom","year":"1999","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD005115-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0002-9149(01)02201-9","article-title":"Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective NSAIDs","volume":"89","author":"Reicin","year":"2002","journal-title":"American Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD005115-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/sj.jhh.1001411","article-title":"The different patterns of blood presure elevation by rofecoxib and nabumetone","volume":"16","author":"Reitblat","year":"2002","journal-title":"Journal of Human Hypertension"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD005115-BIB0084|cit84","first-page":"Abstract 1352","article-title":"Early experience with selective COX-2 inhibitors; safety profile in over 340,000 patient years of use [abstract]","volume":"42","author":"Singh","year":"1999","journal-title":"Arthritis & Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD005115-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1185\/030079903125001712","article-title":"Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory durgs in Spain: results of phase 2 of the VICOXX study","volume":"19","author":"Arboleya","year":"2003","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD005115-BIB0086|cit86","unstructured":"Goldstein J Bello A Fort J Differential rates of UGI symptoms in patients receiving celecoxib versus rofecoxib with and without low dose aspirin for cardiovascular prophylaxis EULAR conference abstracts 2000"},{"key":"10.1002\/14651858.CD005115-BIB0087|cit87","unstructured":"Hawkey C Laine L Mortensen E Treatment of osteoarthritis with rofecoxib, a COX-2 specific inhibitor, was associated with a lower incidence of gastroduodenal ulcers compared to ibuprofen and was comparable to placebo treatment [abstract] Proceedings of the 14th Congress of hte European League Against Rheumatism Glasgow"},{"key":"10.1002\/14651858.CD005115-BIB0088|cit88","first-page":"A232","article-title":"Effect of the COX-2 specificn inhibitor rofecoxib on ulcer formation: a double blind comparison with ibuprofen and placebo [abstract]","volume":"116","author":"Laine","year":"1999","journal-title":"Gasteroenterology"},{"key":"10.1002\/14651858.CD005115-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1046\/j.1365-2036.1999.00529.x","article-title":"Selective inhibition of cyclooxygenase 2 (COX2) with MK0966 is associated with less gastroduodenal damage than aspirin or ibuprofen","volume":"13","author":"Rack","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1002\/14651858.CD005115-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/archinte.160.10.1465","article-title":"Effects of celecoxib and naproxen on renal function in the elderly","volume":"160","author":"Whelton","year":"2000","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD005115-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00045391-200103000-00003","article-title":"Cyclooxygenase-2 specific inhibitors and cardiorenal function: a randomised controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients","volume":"8","author":"Whelton","year":"2001","journal-title":"American Journal of Therapeutics"},{"key":"10.1002\/14651858.CD005115-BIB0092|cit92","first-page":"700","article-title":"Recommendations for a core set of outcome measures for future phase lll clinical trials in knee,hip and hand osteoarthritis.Consensus development at OMERACT III","volume":"24","author":"Bellamy","year":"1997","journal-title":"J Rheum"},{"issue":"21","key":"10.1002\/14651858.CD005115-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of Rofecoxib and Naproxen in patients with rheumatoid arthritis. The VIGOR trial.","volume":"343","author":"Bombardier","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005115-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/rheumatology\/38.8.779","article-title":"Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2","volume":"38","author":"Brooks","year":"1999","journal-title":"British Journal of Rheumatology"},{"key":"10.1002\/14651858.CD005115-BIB0095|cit95","unstructured":"Cannon GW Krupa DA McCormick CL Mehta A Reicin AS Rofecoxib has a lower incidence of increased liver function tests and LFT-related adverse events in comparison to diclofenac [abstact] EULAR, Lisbon 2003"},{"key":"10.1002\/14651858.CD005115-BIB0096|cit96","unstructured":"Cannon GW Krupa D Sperling R Truitt K Two-year efficacy of rofecoxib and diclofenac in treatment of knee and hip osteoarthritis [abstract] Eular, Lisbon 2003"},{"issue":"11","key":"10.1002\/14651858.CD005115-BIB0097|cit97","first-page":"2635","article-title":"Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis","volume":"27","author":"Ehrich","year":"2000","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD005115-BIB0098|cit98","article-title":"Rofecoxib for the treatment of rheumatoid arthritis","author":"Garner","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD005115-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1185\/030079902125000354","article-title":"A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents","volume":"18","author":"Gertz","year":"2002","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD005115-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF02668029","article-title":"Clycooxygenase selectivity and NSAIDS","volume":"3","author":"Glaser","year":"1995","journal-title":"Inflammopharmacology"},{"key":"10.1002\/14651858.CD005115-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1046\/j.1365-2036.2001.01007.x","article-title":"Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomised controlled trials","volume":"15","author":"Hawkey","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1002\/14651858.CD005115-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1136\/bmj.312.7046.1563","article-title":"Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis","volume":"312","author":"David","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD005115-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomised controlled trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD005115-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0014-2999(98)00078-8","article-title":"Comparison of cyclooxygenase 1 and 2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells","volume":"347","author":"Kawai","year":"1998","journal-title":"European Journal of Pharmacology"},{"issue":"19","key":"10.1002\/14651858.CD005115-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1161\/hc4401.100078","article-title":"Cardiovascular thrombotic events in controlled clinical trials of rofecoxib","volume":"104","author":"Konstam","year":"2001","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD005115-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/(SICI)1099-1557(200003\/04)9:2<113::AID-PDS478>3.0.CO;2-2","article-title":"Baseline risk of gastrointestinal disorders among new users of meloxicam, ibuprofen, diclofenac, naproxen and indomethacin.","volume":"9","author":"Lanes","year":"2000","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1002\/14651858.CD005115-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(94)90185-6","article-title":"Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs.","volume":"343","author":"Langman","year":"1994","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD005115-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00004836-198904000-00009","article-title":"Dyspepsia in NSAID users: the size of the problem.","volume":"11","author":"Larkai","year":"1989","journal-title":"J Clin Gastroenterol"},{"key":"10.1002\/14651858.CD005115-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/rheumatology\/keg379","article-title":"Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription event monitoring PEM data","volume":"42","author":"Layton","year":"2003","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD005115-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/bmj.325.7365.624","article-title":"Observational study of upper GI haemorrhage in elderly patients given selective cyclo-oxygenase 2 inhibitors or conventional NSAIDs","volume":"325","author":"Mamdani","year":"2002","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD005115-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(04)16299-5","article-title":"Cyclooxygenase 2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heartfailure outcomes in elederly patients; a population based cohort study","volume":"363","author":"Mamdani M. Juurlink","year":"2004","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005115-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0140-6736(02)11131-7","article-title":"Cox 2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease","volume":"360","author":"Ray","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005115-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0002-9149(01)02201-9","article-title":"Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective NSAIDs","volume":"89","author":"Reicin","year":"2002","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD005115-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/sj.bjp.0701076","article-title":"Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX 2 inhibitor","volume":"121","author":"Riendeau","year":"1997","journal-title":"British Journal of Pharmacology"},{"key":"10.1002\/14651858.CD005115-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD005115-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","article-title":"Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs","volume":"123","author":"Silverstein","year":"1995","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD005115-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00124743-199606000-00005","article-title":"Nonsteroidal antiinflammatory drugs and their effects; the importance of COX \"selectivity\"","volume":"2","author":"Simon","year":"1996","journal-title":"Journal of Clinical Rheumatology"},{"key":"10.1002\/14651858.CD005115-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1001\/archinte.1996.00440130066007","article-title":"Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study","volume":"156","author":"Singh G. Ramey DR. Morfeld D. Shi H. Hatoum HT. Fries","year":"1996","journal-title":"Arch Int Med"},{"key":"10.1002\/14651858.CD005115-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1161\/01.CIR.0000127578.21885.3E","article-title":"Relationship between selective cyclooxygenase 2 inhibitors and acute myocardial infarction in older adults","volume":"109","author":"Solomon","year":"2004","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD005115-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00004836-199310000-00014","article-title":"NSAID-induced gastroduodenal damage: is prevention needed?","volume":"17","author":"Stalnikowicz","year":"1993","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1002\/14651858.CD005115-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/009127000004001005","article-title":"Comparative Inhibitory activity of rofecoxib, meloxicam, diclofenac, naproxen on cox 2 versus cox 1 in healthy volunteers","volume":"40","author":"Hecken","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/14651858.CD005115-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.pharmtox.38.1.97","article-title":"Cyclooxygenases 1 and 2.","volume":"38","author":"Vane","year":"1998","journal-title":"Annual Review of Pharmacology & Toxicology"},{"key":"10.1002\/14651858.CD005115-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1073\/pnas.96.13.7563","article-title":"Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastro-intestinal toxicity: a full in vitro analysis","volume":"96","author":"Warner","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1002\/14651858.CD005115-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0002-8703(03)00398-3","article-title":"Selective Cox 2 inhibition and cardiovascular effects: a review of the rofecoxib development program","volume":"146","author":"Weir","year":"2003","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD005115-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/j.1552-4604.1991.tb03743.x","article-title":"Nonsteroidal antiinflammatory drugs: effect on kidney function","volume":"31","author":"Whelton","year":"1991","journal-title":"Journal of Clinical Pharmacology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD005115\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T12:41:36Z","timestamp":1682944896000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD005115"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2005,1,24]]},"references-count":125,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005115","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,24]]}}}